Technical Analysis for ALXN - Alexion Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 130.21 -2.98% -4.00
ALXN closed down 2.98 percent on Friday, March 22, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Down
See historical ALXN trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 20 DMA Bearish 0.00%
Mar 22 Bollinger Band Squeeze Range Contraction 0.00%
Mar 21 Crossed Above 20 DMA Bullish -2.98%
Mar 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -2.98%
Mar 21 Pocket Pivot Bullish Swing Setup -2.98%
Mar 21 Bollinger Band Squeeze Range Contraction -2.98%
Mar 21 Outside Day Range Expansion -2.98%
Mar 20 20 DMA Resistance Bearish -1.10%
Mar 20 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -1.10%
Mar 20 Bollinger Band Squeeze Range Contraction -1.10%

Older signals for ALXN ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. The company offers Soliris (eculizumab), a therapeutic product for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It also conducts Phase IV clinical trails on Soliris for its usage for the treatment of PNH registry, and aHUS for pediatric and adult; and various Phase II clinical trails for its usage for the treatment of PNH pediatric trial, cold agglutinin disease, MPGN II/C3 nephropathy, hemolytic uremic syndrome, presensitized renal transplant, delayed kidney transplant graft function, ABO incompatible renal transplant, neuromyelitis optica, and myasthenia gravis. In addition, the company develops Asfotase alfa that is under Phase II clinical trail for the treatment of metabolic disorders, including hypophosphatasia; ALXN 1102/1103, which is in Phase I trial for PNH; and ALXN 1007, a novel humanized antibody for treating inflammatory disorders. Further, the company conducts preclinical trails on cPMP for treating metabolic disorders. It serves specialty distributors and specialty pharmacies, which supply physician office clinics, hospital outpatient clinics, infusion clinics, or home health care providers; government agencies; and hospitals, hospital buying groups, pharmacies, other healthcare providers, and distributors. The company sells its products primarily in the United States, Europe, and the Asia Pacific. Alexion Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Cheshire, Connecticut.
Medicine Biopharmaceutical Medical Specialties Organ Systems Healthcare Providers Paroxysmal Nocturnal Hemoglobinuria Metabolic Disorders Acquired Hemolytic Anemia Inflammatory Disorders Myasthenia Gravis Alexion Pharmaceuticals Atypical Hemolytic Uremic Syndrome Genetic Disease Hemolytic Uremic Syndrome Kidney Transplant Renal Transplant
Is ALXN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 140.77
52 Week Low 92.56
Average Volume 1,594,991
200-Day Moving Average 122.2389
50-Day Moving Average 125.643
20-Day Moving Average 133.496
10-Day Moving Average 133.555
Average True Range 3.4395
ADX 24.5
+DI 23.553
-DI 19.395
Chandelier Exit (Long, 3 ATRs ) 128.0015
Chandelier Exit (Short, 3 ATRs ) 136.0185
Upper Bollinger Band 138.4907
Lower Bollinger Band 128.5013
Percent B (%b) 0.17
BandWidth 7.482921
MACD Line 1.8858
MACD Signal Line 2.7067
MACD Histogram -0.8209
Fundamentals Value
Market Cap 29.06 Billion
Num Shares 223 Million
EPS 2.31
Price-to-Earnings (P/E) Ratio 56.37
Price-to-Sales 8.25
Price-to-Book 3.18
PEG Ratio 1.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 137.41
Resistance 3 (R3) 138.17 136.54 136.21
Resistance 2 (R2) 136.54 134.70 136.16 135.81
Resistance 1 (R1) 133.37 133.57 132.56 132.61 135.41
Pivot Point 131.74 131.74 131.33 131.36 131.74
Support 1 (S1) 128.57 129.90 127.76 127.81 125.01
Support 2 (S2) 126.94 128.77 126.56 124.61
Support 3 (S3) 123.77 126.94 124.21
Support 4 (S4) 123.01